Cyclin dependent kinase (CDK)4 inhibitors and their use for treating cancer
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Oct 7, 2003
Grant Date -
N/A
app pub date -
Feb 18, 2000
filing date -
Apr 28, 1997
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Certain derivatives of acridones and benzothiadiazines have been found to have anti-cancer properties by virtue of their specific inhibition of the cyclin D dependant kinase CDK4. These molecules inhibit CDK4 activity more than they inhibit the activity of other such kinases (e.g. CDC2 and CDK2). This specificity results in an improved therapeutic index when used as drugs to treat susceptible cancers.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully